In patients with von Willebrand disease type 2B (VWD type 2B), a disease characterized by gain-of-function mutations in VWF that enhance its spontaneous binding to the platelet GPIbα, increased platelet-VWF binding is associated with thrombocytopathy due to inhibition of αIIbβ3 activation [15]. Here, GP1BA is linked to von Willebrand disease type 2B.